nightclaude · nightly deep dive · 2026-10-03

Veeva at $273.33: Pharma's Operating System on Sale

Veeva Systems compounded FY2023 revenue of $2.16B to $3.20B in FY2026 at 75.0% gross margin and 29.6% operating margin, with $1.42B in cash against only $95.86M in total debt. At $273.33 for a $44.25B market cap, 46.33x trailing earnings and 26.66x forward earnings, the Vault migration off Salesforce is now the entire investment debate.

In life sciences, swapping a validated system risks an FDA inspection, which is why Veeva and its 7,928 employees matter more than any generic AI demo. On $3.20B in FY2026 revenue, Veeva delivered gross profit of $2.41B, operating income of $916.37M and net income of $908.91M, with $1.42B in operating cash flow funding $767.39M in R and D, the economics of an Intuit for pharma rather than a services vendor.

Price has not followed profit. At $273.33, between a $148.05 low and $310.50 high, down 9.1% over one year and down 2.2% over five years, the $37.16B enterprise value pays 34.56x EV to EBITDA on $954.34M of EBITDA while the Street holds a $297.30 target and a buy rating. Against horizontal scale from Salesforce and data scale from IQVIA, Veeva bets that one Vault across Commercial, Development and Data sustains a 29.3% profit margin and 14.4% ROE.

History & Ownership

Veeva Systems Inc. is a Pleasanton, California, industry cloud company incorporated in 2007 as Verticals onDemand, Inc. and renamed Veeva Systems Inc. in April 2009. It now employs 7,928 people serving life sciences in North America, Europe, Asia Pacific, the Middle East, Africa and Latin America. At a last close of $273.33, Veeva carries a market capitalization of $44.25B and an enterprise value of $37.16B, pricing at a trailing P/E of 46.33 and forward P/E of 26.66, a multiple that only makes sense in the context of its origin as a single vertical obsession that compounded into a platform.

From Salesforce tenant to Vault landlord

Veeva began as a life sciences CRM built on top of another platform, a classic vertical SaaS wedge. Founder and CEO Peter Gassner, who remains responsible for strategic direction, product direction and operations (per veeva.com, Aug 2026), positioned the company not as horizontal CRM but as the regulated system of record for pharma. That choice defined the next 15 years: Commercial Cloud with Vault CRM Suite, PromoMats, Medical and Crossix analytics, then Development Cloud with Clinical Platform, Clinical Data Management, Safety, Regulatory Information Management and Quality Cloud, plus Data Cloud assets including OpenData, Link, Compass and CRM Pulse.

The financial arc shows a deliberate migration from rented infrastructure to owned Vault infrastructure. SEC EDGAR XBRL facts put revenue at $2.16B in FY2023, $2.36B in FY2024, $2.75B in FY2025 and $3.20B in FY2026, while net income moved from $487.71M to $525.71M to $714.14M to $908.91M over the same period. Operating income tells the investment story, dipping to $429.33M in FY2024 during heavy R and D and platform transition, then expanding to $691.43M in FY2025 and $916.37M in FY2026. Research and development rose every year, from $520.28M in FY2023 to $767.39M in FY2026. The balance sheet was built to fund that transition internally, with assets growing to $8.98B in FY2026, stockholders equity to $7.21B, liabilities of only $1.76B, total debt of $95.86M and cash and cash equivalents of $1.42B. Free cash flow reached $1.42B in FY2026 on operating cash flow of $1.42B, against gross margin of 75.0%, operating margin of 29.6% and profit margin of 29.3%.

The Vault CRM split was the defining milestone. Management described the fiscal 2027 second quarter as its best CRM quarter ever, with broad commercial strength and new global Vault CRM commitments (per veeva.com, Aug 2026 and investing.com, Aug 2026). In industry terms, Veeva did what Model N, IQVIA and Oracle Health never fully executed: it converted services led implementations into high margin subscription scale, then used consulting and managed services to deepen moats rather than dilute margins.

Ownership and founder character

Veeva is institutionally owned but founder led. Insiders hold 8.62% and institutions hold 93.38% across 1,550 institutions, with institutions holding 102.19% of float on a lending adjusted basis. That structure explains the $310.50 52 week high and $148.05 low, down 9.1% over one year and down 2.2% over five years despite compounding fundamentals, classic crowded long volatility around Vault migration and pharma IT budgets. The Street remains constructive, with a mean target of $297.30 and a buy recommendation.

• Founder control without dual class drama: Gassner has led since 2007, supported by a long tenured operating bench including CFO Brian Van Wagener and Chief of Staff Nitsa Zuppas (per veeva.com, Aug 2026), a continuity model closer to Intuit or Adobe than to acquisitive healthcare IT rollups.
• Public Benefit Corporation discipline: Veeva operates as a for profit Public Benefit Corporation committed to making its industries more productive and creating high quality employment, with directors legally balancing shareholders, customers and employees (per veeva.com, Apr 2023). It is stakeholder language backed by a $7.21B equity cushion and minimal leverage, not by adjusted metrics.
• Capital allocation: Repurchases were $169.95M in FY2026 against $0.00 in FY2025, modest relative to $1.26B in free cash flow on a trailing basis, signaling reinvestment in Vault, Data Cloud and consulting over financial engineering.

Gassner character is product authoritarianism in the best sense: slow to expand domains, relentless on data model depth, willing to sacrifice a year of operating income to own the stack. That is why Veeva, unlike generic CRM or EDC vendors, can price at $44.25B on $3.20B of revenue and still retain pharma boards. The risk is the same as the strength, single vertical concentration and founder dependence, but ownership, balance sheet and Vault traction show a company built to outlast cycles.

Business Model & Strategy

Veeva Systems sells industry specific cloud software to pharmaceutical, biotechnology and life sciences customers globally, with 7,928 employees supporting deployments across North America, Europe, Asia Pacific, the Middle East, Africa and Latin America. The company, incorporated in 2007 in Pleasanton, California, generated $3.20B in revenue in FY2026, up from $2.75B in FY2025 and $2.36B in FY2024, with gross profit of $2.41B and operating income of $916.37M. That profile, 75.0% gross margin and 29.6% operating margin, is the signature of a vertical SaaS monopolist, not a services business.

What it sells and to whom

Veeva organizes around three product clouds plus services, all built on the Vault platform. The buyer is not IT, it is regulatory, clinical, safety, medical and commercial operations inside drug makers and contract research organizations. That focus is the wedge against horizontal vendors.

Recurring versus one time revenue

Subscriptions are the engine. Veeva reported total revenues of $928.0M with subscription revenues of $766.8M for the quarter ended July 31, 2026, per ir.veeva.com, August 2026. That mix, more than four dollars of subscription for every dollar of services in the quarter, explains why gross margin holds at 75.0% and why operating cash flow reached $1.42B in FY2026. Professional services, implementation and deployment planning, solution design, data migration, training and managed administration, are deliberately attached to software adoption. They accelerate go lives and expansions but do not carry the margin or renewal profile of subscriptions. Against IQVIA, which blends large services and contract research with technology, and against Salesforce, which monetizes horizontal seats across industries, Veeva monetizes validated, life sciences specific workflows where renewal is tied to regulatory continuity, not discretionary IT spend.

Strategy and competitive flywheel

The strategy is land with one Vault, then expand across Vaults. A customer may start in RIM or Quality, then add Clinical, Safety and PromoMats because documents, data and workflows already live in Vault. The most consequential land motion is Vault CRM Suite, the migration path off Salesforce CRM. Vault CRM ended that July quarter with more than 180 customers live, per finance.yahoo.com, August 2026, a concrete marker that the replacement cycle is working.

• Platform consolidation: one Vault content model across commercial and development reduces integrations that Oracle, Medidata and point vendors such as MasterControl solve separately.
• Data compounding: OpenData, Link, Compass and Crossix improve as adoption grows, giving commercial teams targeting and measurement that a generic CRM plus third party data cannot replicate.
• R and D reinvestment: research and development expense of $767.39M in FY2026 funds depth in validated applications where horizontal players underinvest.
• Balance sheet optionality: cash and cash equivalents of $1.42B against total debt of $95.86M, with total assets of $8.98B and stockholders equity of $7.21B, lets Veeva fund long regulated sales cycles without leverage.

The economic engine is therefore high gross dollar retention on subscriptions, operating leverage from a common Vault code base, and net income of $908.91M on $3.20B of revenue. Veeva does not win by selling more seats. It wins by becoming the system of record for content, data and engagement that a drug cannot go to market without.

Segments & Products

Veeva is a pure play life sciences cloud, not a horizontal SaaS vendor with a pharma vertical. That focus explains both the P and L and the moat. SEC XBRL revenue was $3.20B in FY2026, up from $2.75B in FY2025, $2.36B in FY2024, $2.16B in FY2023 and $1.85B in FY2021, with FY2026 gross profit of $2.41B, operating income of $916.37M and net income of $908.91M. At $273.33 the market values that at $44.25B, or $37.16B enterprise value, a premium that only makes sense if the three clouds below keep expanding seats, modules and data subscriptions inside already captured accounts.

Two engines, one regulated system of record

Commercial is the installed base business. Vault CRM Suite manages healthcare professional engagement, sampling, content approval through PromoMats and Medical, and closed loop measurement through Crossix. Data Cloud monetizes the exhaust: OpenData for customer reference data, Link for key opinion leader depth, Compass for de-identified longitudinal patient data, and CRM Pulse for access and multichannel metrics. Development is the second engine: clinical execution and data management, pharmacovigilance with Safety, regulatory information management with RIM, and document and process control with Quality Cloud, including consumer products adjacencies. Services are implementation, data migration, integration, training and outsourced administration, the glue for multi Vault deployments such as large multi-Vault footprints at large sponsors.

End markets are global pharma, biotech, MedTech, CROs and sponsors across North America, Europe, Asia Pacific, Middle East, Africa and Latin America from Pleasanton with 7,928 employees. That geographic and buyer breadth matters because Veeva prices per user, per Vault and per data subscription, then expands as customers consolidate additional functions on the same Vault platform.

Pricing power is regulatory, not just UX

Gross margin of 75.0%, operating margin of 29.6% and profit margin of 29.3%, with return on equity of 14.4%, signal pricing power rooted in validation and switching cost. A CRM rep can be retrained, a validated clinical, safety, regulatory or quality system cannot be ripped out without revalidation, retraining and audit risk. Balance sheet reinforces it: $1.42B in cash against only $95.86M in total debt and $7.21B in equity on $8.98B in assets, plus $1.42B in FY2026 operating cash flow. Customers fund Veeva in advance, Veeva funds R and D of $767.39M in FY2026, up from $693.08M in FY2025 and $629.03M in FY2024, without leverage.

Competition is direct and named. Veeva states its CRM primarily competes with Salesforce and that Data Cloud and Crossix compete with IQVIA Holdings, Ipsos Group and Definitive Health, per fintel.io reporting the March 2026 10-K. That frames the current reset: Veeva moved CRM off Salesforce onto native Vault CRM, generally available since April 2024, while Salesforce launched Life Sciences Cloud co-developed with IQVIA. Scale of the migration race was more than 115 live Vault CRM deployments with nine of the top 20 biopharmas committed, versus 70 plus customers claimed for Salesforce Life Sciences Cloud, per tellius.com, Feb. 2026.

Growth drivers now

• Vault CRM migration: convert the legacy Salesforce based base to Vault, add Medical, PromoMats and Nitro style analytics per seat. Momentum was visible when total revenue reached $928.0M with subscription revenue of $766.8M in the July 2026 quarter, per veeva.com, Aug. 2026, following $789.1M and $659.2M a year earlier, per veeva.com, Aug. 2025.
• Data attach: OpenData, Link, Compass and Crossix displace third party data spend, especially where IQVIA is both supplier and rival. Analytics is the wedge for AI agents for targeting, next best action and omnichannel measurement.
• Development depth: Clinical, Safety, RIM and Quality sell to R and D budgets that are stickier than commercial headcount, expanding from top 20 pharma into mid biotech, CROs and MedTech.

The bear case is concentration in life sciences cyclicality and execution on a once in 15 year CRM cutover into a Salesforce and IQVIA counterattack. The bull case is that Veeva already did the hard part, turning $2.16B in FY2023 revenue into $3.20B in FY2026 while lifting operating income from $459.09M to $916.37M, and now gets to upsell data and AI on top of a system customers cannot easily leave.

Operations & Go-to-Market

Veeva Systems Inc. makes nothing physical. There are no plants, no contract manufacturers, no inventory turns to manage. Delivery is pure cloud software plus the people who install, validate and run it, all coordinated from Pleasanton, California where the company has been headquartered since its 2007 founding as Verticals onDemand. That asset light model supports $3.20B in FY2026 revenue, per SEC EDGAR FY XBRL facts, with 7928 employees, 75.0% gross margin and 29.6% operating margin. The operating question is not throughput, it is control of the stack and depth of enterprise penetration.

One Platform Delivered As Three Clouds

Veeva delivers on its proprietary Veeva Vault platform, which unifies sales, marketing, medical and service teams in a single Vault database with shared data and content, per sec.gov, Jan 2026. The commercial logic is land with a regulated workflow, then expand across Vault, data and services. Professional and support services are not an afterthought, they are the delivery footprint: implementation and deployment planning, requirements analysis, solution design and configuration, environment management, data migration, systems integration, training and ongoing managed services including outsourced systems administration.

Sales Model: Direct, Regulated, Sticky

Veeva sells direct to life sciences enterprises in North America, Europe, the Asia Pacific, the Middle East, Africa and Latin America. There is no channel, no reseller layer, no consumer funnel. Deals start as a single Vault or CRM deployment inside a therapeutic franchise or a quality or regulatory function, then expand user by user and Vault by Vault because validation, audit trails and 21 CFR Part 11 style compliance make rip and replace painful. That is why services attach matters. Consulting and managed administration raise switching costs while funding the next module sale, a sharp contrast to horizontal SaaS vendors that rely on self serve volume. The model shows in leverage: FY2026 operating income was $916.37M on $3.20B revenue, up from $691.43M on $2.75B in FY2025, per SEC EDGAR FY XBRL facts.

Vertical Integration: The Salesforce Break

The central operational bet is full stack ownership. Veeva CRM long ran on the Salesforce platform, but Vault CRM launched as a purpose built solution on Vault in April 2024, per clarkstonconsulting.com, Sept 2025, and Veeva did not renew the Salesforce agreement on expiry on September 1, 2025, per intuitionlabs.ai, April 2025. Legacy Veeva CRM will be supported until December 31, 2029, per sec.gov, Jan 2026, forcing a managed migration window from 2026 to 2029. Momentum is now measurable, with more than 180 customers live including five top 20 biopharmas, per veeva.com, Aug 2026, which described it as Vault CRM had its best quarter ever, per morningstar.com, Aug 2026. Competitively this redraws the field into Veeva Vault CRM versus Salesforce Life Sciences Cloud co developed with IQVIA, per g-co.agency, Aug 2026, with Oracle and IQVIA competing on adjacent data and trial layers. Veeva funds independence with R and D, spending $767.39M in FY2026 versus $693.08M in FY2025 and $629.03M in FY2024, per SEC EDGAR FY XBRL facts, to own database, content, analytics and AI agents rather than pay platform rent.

Financials

Veeva Systems has compounded from a $2.16B revenue base in FY2023 to $3.20B in FY2026, per EDGAR, with no down year in the pack: $2.36B in FY2024 per EDGAR, then $2.75B in FY2025 per EDGAR. That is a three year climb built on subscription seats across Commercial Cloud and Development Cloud, not one time services. The momentum carried into the current year, with total revenues of $928.0M, up 18% year over year, and subscription revenues of $766.8M, up 16% year over year, for the quarter ended July 31, 2026, per ir.veeva.com, Aug 2026. Management frames the path as a march toward a $6B revenue run rate by 2030, per ir.veeva.com, Mar 2026, which tells you how it sees Vault CRM, Clinical, Safety and Data Cloud layering rather than replacing each other.

Profitability is classic best in class vertical SaaS. Gross profit was $2.41B in FY2026 on $3.20B of revenue per yfinance, for a 75.0% gross margin per yfinance. That gross profile is what separates Veeva from horizontal services businesses and from data heavy rivals like IQVIA, where people drive cost of revenue. Operating leverage returned after the FY2024 dip: operating income was $459.09M in FY2023 per EDGAR, then $429.33M in FY2024 per EDGAR, then $691.43M in FY2025 per EDGAR, then $916.37M in FY2026 per EDGAR, for a 29.6% operating margin per yfinance. Net income tracked it, at $487.71M in FY2023 per EDGAR, $525.71M in FY2024 per EDGAR, $714.14M in FY2025 per EDGAR and $908.91M in FY2026 per EDGAR, a 29.3% profit margin per yfinance. Diluted EPS was $3.00 in FY2023 per yfinance, $3.22 in FY2024 per yfinance, $4.32 in FY2025 per yfinance and $5.44 in FY2026 per yfinance. Returns remain high for a software compounder, with 14.4% ROE and 7.6% ROA per yfinance, while R and D reinvestment rose every year to $767.39M in FY2026 per EDGAR, up from $520.28M in FY2023 per EDGAR.

The balance sheet is fortresslike. Total assets were $8.98B in FY2026 per EDGAR, against only $1.76B of total liabilities per EDGAR, leaving $7.21B of stockholders equity per EDGAR, up from $3.72B in FY2023 per EDGAR. Cash and cash equivalents were $1.42B in FY2026 per EDGAR, up from $1.12B in FY2025 per EDGAR, against total debt of only $95.86M in FY2026 per yfinance. That is net cash by a wide margin, a deliberate contrast to levered life sciences tools peers and to the Salesforce platform history Veeva just exited. Free cash flow conversion is the tell: operating cash flow was $1.42B in FY2026 per yfinance and free cash flow was $1.42B in FY2026 per yfinance, up from $1.09B in FY2025 per yfinance, $911.34M in FY2024 per yfinance and $780.47M in FY2023 per yfinance, essentially converting all of operating income to cash.

Capital allocation and valuation

Veeva does not pay a dividend disclosed in the pack and hoards optionality in cash. FY2026 marks the first buyback in the series, with repurchase of capital stock of $169.95M per yfinance, versus $0.00 in FY2025 per yfinance. At $273.33 per yfinance, down 9.1% over one year per yfinance and sitting between a $148.05 52 week low and a $310.50 52 week high per yfinance, the company carries a $44.25B market cap and $37.16B enterprise value per yfinance. That prices FY2026 at a 46.33 trailing P and E per yfinance, 26.66 forward P and E per yfinance and 34.56 EV to EBITDA per yfinance on $954.34M of EBITDA per yfinance, versus a $297.30 mean target and buy recommendation per yfinance. You pay for durability here, funded internally.

Competitive Landscape & Moat

Veeva Systems is the vertical SaaS standard for life sciences, a position priced as such at $273.33 per share, a $44.25B market cap and $37.16B enterprise value, 46.33 times trailing earnings and 34.56 times EBITDA. The financial signature is pure vertical monopoly economics. Revenue reached $3.20B in FY2026, up from $2.75B in FY2025 and $2.36B in FY2024, with gross profit of $2.41B, a 75.0% gross margin, operating income of $916.37M for a 29.6% operating margin, and net income of $908.91M for a 29.3% profit margin. That combination funds $767.39M in annual R and D and converts to $1.42B in operating cash flow against only $95.86M in total debt and $1.42B in cash, with $7.21B in stockholders equity on $8.98B in assets.

Three battlegrounds, different rivals

Veeva fights on three fronts, and no single rival contests all three. Veeva has begun migrating Veeva CRM customers to Vault CRM built on its own Vault platform, with legacy support until December 31, 2029 (per sec.gov, January 2026). That migration defines the commercial battle, where Veeva's CRM solutions primarily compete with Salesforce, which has developed a life sciences industry specific CRM application, while IQVIA has licensed its CRM software to Salesforce (per fintel.io, March 2026). Management pointed to broad strength in commercial software and record CRM performance in its most recent quarter (per investing.com, August 2026), a direct test of Vault CRM against Salesforce Life Sciences Cloud, built on the Salesforce Customer 360 platform (per salesforce.com, May 2025).

Where Veeva leads, where it lags

Veeva leads where regulation meets workflow. Commercial Cloud bundles Vault CRM Suite, PromoMats for compliant content and digital asset management, Medical, and Crossix analytics into one commercial system of record. Development Cloud does the same for Clinical Platform, Clinical Data Management, Safety, RIM, and Quality Cloud for life sciences and consumer products, plus Business Consulting and implementation services. No named rival offers that breadth in one validated Vault. IQVIA, Dassault Systemes, OpenText, Oracle and Honeywell each compete with certain Development Cloud or Quality applications, but not the suite (per fintel.io, March 2026).

Veeva lags where scale is Horizontal. Salesforce brings the general CRM platform, distribution, and AI stack that a 7,928 person Veeva cannot match rep for rep. IQVIA brings the longitudinal patient, prescribing, and payer data estate that makes Compass and Crossix compete uphill. Veeva Data Cloud products and Crossix compete directly with IQVIA, Ipsos, Definitive Healthcare and smaller analytics providers (per fintel.io, March 2026). Oracle brings entrenched clinical and ERP footprints, Dassault brings Medidata in clinical trials, OpenText brings content management. Veeva closed part of that data gap when its long dispute with IQVIA was resolved toward collaboration and integration, a theme highlighted around its fiscal Q2 results (per nasdaq.com, August 2025).

The moat: validation, switching cost, and data flywheel

• Regulated switching costs. Vault CRM, Safety, RIM, Quality and Clinical are validated, audit trailed systems of record. Rip and replace means revalidation, SOP rewrites, retraining of field, medical, regulatory and quality teams, and risk to FDA and EMA inspections. That is why Vault, not features alone, retains accounts.
• Installed base as distribution. With $3.20B in FY2026 revenue and 17.6% year over year growth, Veeva lands new Vaults inside existing commercial and development footprints. Professional services for implementation, migration, data migration, integration and managed administration deepen entrenchment.
• Data flywheel. OpenData customer reference data, Link deep key opinion leader data, Compass de identified longitudinal patient data, Pulse access and multichannel metrics, and Crossix brand analytics improve as more customers run commercial execution on Veeva. IQVIA still owns the deepest third party data, but Veeva owns the workflow where that data is activated.
• Scale economics to out invest niches. A 75.0% gross margin and 29.6% operating margin, 14.4% ROE, and $1.42B in operating cash flow let Veeva sustain $767.39M in R and D while carrying minimal debt. Point vendors cannot fund Vault level platform R and D across commercial, clinical, safety, regulatory and quality at once.

The risk is the moat test now underway. The Salesforce divorce turned a 15 year partner into a direct life sciences CRM rival co developed with IQVIA, forcing every large pharma to choose Vault CRM or Salesforce between now and 2029. If Vault migration stalls, switching cost cuts the other way. If it succeeds, Veeva owns its platform, its margin, and the industry cloud outright.

Key Risks

• 1. Vault CRM replatforming: moving the CRM franchise off Salesforce onto Veeva Vault over the legacy support window while Salesforce sells directly against it.
• 2. Single vertical dependence: all $3.20B of FY2026 revenue comes from life sciences, so a pharma pullback hits every cloud at once.
• 3. IQVIA and the data moat: Veeva Data Cloud and Crossix compete with the industry data incumbent that also litigates.
• 4. Perfection pricing: $273.33 and a $44.25B market cap leave no room for a stalled migration or a slower year.
• 5. The reinvestment treadmill: elite 75.0% gross and 29.6% operating margins depend on sustaining heavy R and D and services execution.

1. The Salesforce divorce is now a direct competition

Veeva built its Commercial Cloud, including Vault CRM Suite, PromoMats, MedTech and Crossix, inside an industry where Salesforce was once infrastructure. That era is over. Veeva is migrating customers to Vault CRM on its own Vault platform, with legacy support discussed through December 2029 and most moves expected from 2026 to 2029, per clarkstonconsulting.com, September 2025 and intuitionlabs.ai, April 2025. The alternative path is Salesforce Life Sciences Cloud, which frames every renewal as a competitive bakeoff through the 2030s, per customertimes.com, September 2026.

Early traction is real, with 100 Vault CRM customers live cited alongside a resolved IQVIA dispute, per theglobeandmail.com, August 2025, and new Vault CRM selections including Biogen and Regeneron, per simplywall.st, August 2026 and ir.veeva.com, September 2026. The risk is execution at scale across 7,928 employees, global validations, integrations, and change management at top 20 pharmas. A slip, a defections to Salesforce, or discounting to hold migrations would impair the $2.75B to $3.20B revenue climb from FY2025 to FY2026 and the forward P and E of 26.66 that assumes it continues.

What would confirm this risk: lengthening Vault CRM go lives, disclosed migration delays, or losses of legacy CRM seats to Salesforce Life Sciences Cloud.

2. One industry pays all the bills

Veeva discloses cloud software for life sciences in North America, Europe, Asia Pacific, Middle East, Africa and Latin America, but that geographic spread masks vertical concentration. Development Cloud for clinical, safety, regulatory and quality, Commercial Cloud for CRM and content, and Data Cloud for OpenData, Link, Compass and Pulse all ultimately bill the same pharma and biotech budget. When rep counts, launches, or trial starts slow, Veeva cannot offset with banking, retail or government the way Salesforce, Oracle or Microsoft can.

That concentration magnified the FY2021 to FY2024 stall when operating income fell to $429.33M from $505.50M even as revenue grew to $2.36B, before rebounding to $916.37M on $3.20B in FY2026. The Q2 FY2027 print of $928.0M in total revenue, up 18% year over year, with subscription revenue of $766.8M, per ir.veeva.com, August 2026, shows momentum, but it also shows how tightly Veeva tracks commercial hiring and R and D spend.

What would confirm this risk: pharma restructuring, reduced salesforce sizes, or trial delays that slow subscription and services growth together.

3. IQVIA owns the data Veeva wants to replace

Veeva Compass, OpenData, Link, Crossix and CRM Pulse attack reference data, longitudinal patient data, and measurement that IQVIA has sold for decades with CRO and real world data bundling. Veeva calls this Data Cloud, but IQVIA can bundle data with services, discount against Vault, or restrict interoperability, a tension flagged as a restrictive long running lawsuit risk, per trefis.com, January 2026. Management pointed to a strategic resolution with IQVIA alongside raised billings guidance, per theglobeandmail.com, August 2025, yet coexistence is not friendship when both claim to be foundational platforms.

Losing here matters because data raises switching costs for Vault CRM and Clinical Platform. With total assets of $8.98B and stockholders equity of $7.21B against only $95.86M of total debt and $1.42B of cash at FY2026, Veeva can fund the fight, but it cannot acquire its way past IQVIA scale.

What would confirm this risk: renewed IQVIA litigation, adverse data access rulings, or Compass and Crossix win rates that stall while IQVIA renews incumbents.

4. The multiple assumes flawless conversion

At $273.33, Veeva carries a $44.25B market cap and $37.16B enterprise value on FY2026 net income of $908.91M and diluted EPS of $5.44, pricing to a trailing P and E of 46.33 and EV to EBITDA of 34.56. Consensus is already positioned for delivery, with a mean target of $297.30 and a buy recommendation, while the tape shows impatience, with a 1 year return of negative 9.1% and a 5 year return of negative 2.2% between a 52 week low of $148.05 and high of $310.50 and a 5 year range of $151.10 to $325.25.

The bull case is operating leverage, with profit margin of 29.3%, ROE of 14.4% and free cash flow of $1.26B supporting the forward P and E of 26.66. The bear case is that any air pocket in Vault CRM conversion compresses both growth at 17.6% year over year and that multiple at once, a classic vertical SaaS derating where Salesforce and IQVIA need only to delay decisions to inflict pain.

What would confirm this risk: a quarter where the $928.0M pace, per ir.veeva.com, August 2026, decelerates while the stock still trades near current levels, forcing estimate cuts.

5. Margins are elite because spending never stops

Veeva posts 75.0% gross margin, 29.6% operating margin and 29.3% profit margin, with operating cash flow of $1.42B in FY2026 funding $767.39M of R and D, up from $382.04M in FY2021 and $693.08M in FY2025. That spend built Clinical Data Management, Safety, RIM, Quality Cloud and Business Consulting, plus ongoing implementation, migration, training and managed services. Liabilities of $1.76B are modest, and the $169.95M of capital stock repurchased in FY2026 signals confidence, but services heavy migrations are lower margin and resource intensive.

If Vault CRM, EDC, CTMS and Safety rollouts require more customization, validation work or AI rebuilds than planned, R and D and services costs can grow faster than the $3.20B revenue base, repeating the FY2021 to FY2024 pattern where higher R and D coincided with lower operating income.

What would confirm this risk: operating margin retreating from 29.6% while R and D and professional services headcount grow faster than subscription revenue.

Lessons

Veeva Systems Inc., the Pleasanton life sciences cloud vendor built on Veeva Commercial Cloud, Veeva Development Cloud and Veeva Data Cloud, converts narrow domain dominance into numbers most horizontal software vendors cannot touch: 75.0% gross margin, 29.6% operating margin and 29.3% profit margin on $3.20B of FY2026 revenue.

1. Vertical depth beats horizontal breadth

Veeva does not sell generic CRM or generic content management. It sells Veeva Vault CRM Suite, Veeva PromoMats and Veeva Crossix for commercial, plus Veeva Clinical Platform, Veeva Safety, Veeva RIM and Veeva Quality Cloud for development, plus Veeva OpenData, Veeva Link and Veeva Compass for data. That end to end ownership of regulated workflows explains $2.41B of gross profit on $3.20B of FY2026 revenue and a 75.0% gross margin. The lesson: in regulated industries, the vendor that owns compliance, content and data together keeps pricing power that a horizontal seat license never earns.

2. Reinvest through the P and L while expanding margins

Veeva raised ResearchAndDevelopmentExpense to $767.39M in FY2026 from $520.28M in FY2023, while OperatingIncomeLoss expanded to $916.37M in FY2026 from $459.09M in FY2023 and NetIncomeLoss expanded to $908.91M in FY2026 from $487.71M in FY2023. Revenue grew to $3.20B in FY2026 from $2.16B in FY2023. The lesson: elite vertical SaaS can fund Vault, Clinical Data Management and Safety innovation out of current earnings and still show operating leverage, with return on equity at 14.4% and return on assets at 7.6%.

3. A net cash balance sheet is a competitive weapon

At FY2026 year end Veeva held $1.42B in CashAndCashEquivalentsAtCarryingValue against only $95.86M of Total Debt, with Total Assets of $8.98B, Total Liabilities of $1.76B and StockholdersEquity of $7.21B. Operating Cash Flow was $1.42B and Free Cash Flow was $1.42B in FY2026. The lesson: with 7,928 employees serving global pharma and biotech, that surplus cash lets Veeva fund multi year platform migrations, professional services and Business Consulting without needing capital markets, while customers trust a vendor that will outlive their validation cycles.

4. Flat stock prices can hide compounding

Veeva closed at $273.33 on 2026-10-02, between a 52 week low of $148.05 and a high of $310.50, with a 1 year return of -9.1% and a 5 year return of -2.2%. Over the same arc the business compounded from $2.16B to $3.20B in revenue and $487.71M to $908.91M in net income, with diluted EPS moving to $5.44 from $3.00. The market now prices that record at $44.25B of market cap, $37.16B of enterprise value, 46.33 trailing P and E, 26.66 forward P and E and 34.56 EV to EBITDA against a $297.30 analyst target mean and a buy recommendation. The lesson: judge migrations and multiple compression on audited revenue, cash and earnings, not on price memory, and let 17.6% revenue growth do the work.